Freshly Funded Symic Bio Plays In The Matrix

 
• By Eleanor Malone

Emerging Company Profile: Symic Bio recently raised $30m in a Series B financing. CEO Ken Horne talks about the firm's therapeutic focus on the body's extracellular matrix as a therapeutic target, and its two lead programs in peripheral vein graft failure prevention and knee osteoarthritis.

Emerging Company Profile Regular column feature image Version 2

More from Start-Ups & SMEs

More from Business